Chinese Pharma Private Securities TransactionsAs the economy recovers from the Great Recession, a number of regulatory violations that had been somewhat dormant for the past few years are once again showing up on the radar screen. With increasing number of deals, we're also seeing rising numbers of enforcement actions involving misconduct atte... Read On